Home Newsfeeds AbbVie Says Reported GAAP Earnings, Adj. Earnings For Q4 Are Expected To Include Acquired IPR&D Milestones, Expense Of $243M On Pre-Tax Basis; Says FY22 Adj. EPS Including Impact Of Q4 Acquired IPR&D, Milestones Expense Is $13.70-$13.74 Vs $13.85 Est.

AbbVie Says Reported GAAP Earnings, Adj. Earnings For Q4 Are Expected To Include Acquired IPR&D Milestones, Expense Of $243M On Pre-Tax Basis; Says FY22 Adj. EPS Including Impact Of Q4 Acquired IPR&D, Milestones Expense Is $13.70-$13.74 Vs $13.85 Est.

-SEC Filing

byMichael Horton

January 6, 2023

1 minute read

-SEC Filing

What’s Going On With Canopy Growth Stock?

By Ryan Gustafson

June 8, 3:27 PM

Canopy Growth Corporation (NASDAQ: CGC) shares are trading lower. The company announced the expansion of its product portfolio for the Quebec market in partnership with VASCO Cannabis Inc on Thursday.

CGC